Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

AI Company GEDI Cube And Renovaro Biosciences Announce A Binding, Exclusive Letter Of Intent To Merge, Accelerating Fight Against Cancer; Terms Not Disclosed

Author: Benzinga Newsdesk | August 09, 2023 09:08am

Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer
- In silico detection for 12 additional cancers, including pancreatic
- More than 2,600 proprietary biomarker panels
- Rapidly expanding to other cancers and diseases
Innovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024
Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision, in silico drug discovery

Posted In: ENOB RENB